SCHEMBL24944387

SCHEMBL24944387

CCc1cc2ccc(C(C)(C)C)cc2o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.37
PON1 P27169 1/20 0.36
MAOB P27338 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
DRD4 P21917 1/20 0.33
HTR2C P28335 2/20 0.33
ADAM17 P78536 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2B P41595 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14157792 0.86 ADAM17 (0.44) HDAC6PON1ALDH1A1HPGDALOX15
SCHEMBL2056131 0.84 HRH3 (0.40) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL13071172 0.78 ADAM17 (0.50) PON1MAOBALDH1A1HPGDALOX15
SCHEMBL15430954 0.76 TSHR (0.38) PON1MAOBALDH1A1HPGDALOX15
SCHEMBL10173404 0.76 ALDH1A1 (0.38) PON1MAOBALDH1A1HPGDALOX15
SCHEMBL13699027 0.76 ALDH1A1 (0.44) HDAC6MAOBHDAC3HDAC1HDAC2
SCHEMBL10222551 0.76 CYP1A2 (0.45) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL2056154 0.74 CA12 (0.46) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL12967200 0.74 APP (0.41) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL27890920 0.74 APP (0.41) HDAC6MAOBHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF ROCK1, ROCK2, RHOA HDAC6 787/4885PON1 1499/4885MAOB 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.